GELS vs GRFS vs PODD Stock Comparison

Gelteq, Grifols and Insulet Prices as of Oct 26, 2026 Peers: Industry group
GELS Gelteq Ltd
$0.45 -18.2% 1M -63.7% 1Y
Market cap
$4.08M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Manufacturing Healthcare
GRFS Grifols SA
$7.92 +7.8% 1M -16.3% 1Y
Market cap
$5.52B
P/E
11.9x
Revenue (TTM)
—
Div. yield
–
Biotechnology Healthcare
5 wins
PODD Insulet Corp
$149.26 +9.6% 1M -53.5% 1Y
Market cap
$10.38B
P/E
27.7x
Revenue (TTM)
$3.05B
Div. yield
–
Medical Devices Healthcare
2 wins

Head to Head

7 decided of 12

Grifols leads on 5 of the 12 questions below (Grifols 5, Insulet 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGELSGRFSPODDLeader
Larger companyMarket capitalisation $4.08M $5.52B $10.38B PODD
Cheaper on earningsLower P/E, profitable companies only — 11.9x 27.7x GRFS
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 8.4x 24.3x GRFS
Faster revenue growthRevenue growth, trailing twelve months — — +29.4% –
More profitableNet margin, trailing twelve months — — 12.3% –
Better return on capitalReturn on invested capital — — 16.9% –
Less leveragedLower net debt / EBITDA — — 0.7x –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -63.7% -16.3% -53.5% GRFS
Better 5-year returnAnnualised price return, 5 years — -9.9%/yr -13.0%/yr GRFS
Less volatileAnnualised volatility, 1 year 159.8% 32.4% 46.9% GRFS
Higher overall scoreMean of the five percentile scores vs peers — 57/100 82/100 PODD

Percentile Scorecard

GELSGRFSPODD

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGELSGRFSPODD
Valuation – 99 #6 of 626 76 #55 of 228
Growth – – 95 #12 of 221
Profitability – – 95 #11 of 208
Financial Health 67 #5 of 13 14 #566 of 658 52 #115 of 239
Shareholder Returns – 56 #161 of 368 93 #10 of 137
Overall – 57 82
  • GELS ranked among 13 companies in Pharma Services
  • GRFS ranked among 673 companies in Pharmaceuticals and Biotechnology
  • PODD ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGELSGRFSPODDSPY
1 month -18.2%+7.8%+9.6% -0.8%
3 months -31.8%+2.2%-9.5% +3.5%
6 months -35.3%-2.6%-20.7% +7.0%
Year to date -43.8%-15.3%-47.5% +12.2%
1 year -63.7%-16.3%-53.5% +13.0%
3 years —+1.0%+11.9% +86.3%
3 years, per year —+0.3%+3.8% +23.1%
5 years —-40.5%-50.1% +68.6%
5 years, per year —-9.9%-13.0% +11.0%
10 years —-46.6%+294.6% +258.0%
10 years, per year —-6.1%+14.7% +13.6%

Risk

MeasureGELSGRFSPODDSPY
Volatility, 1Y 159.8%32.4%46.9% 12.7%
Downside volatility, 1Y 122.0%34.1%54.4% 12.7%
Beta vs S&P 500, 1Y 2.060.950.27 1.00
Return / volatility, 1Y -0.40-0.50-1.14 1.02
Max drawdown, 5Y -91.9%-58.9%-63.0% -25.4%
From 52-week high -70.6%-18.5%-56.9% -1.8%
52-week high $1.53$9.72$346.36 $779.14
52-week low $0.39$7.02$130.47 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGELSGRFSPODD
P/E now vs peer median —median 36.5x 11.9xmedian 17.1x 27.6xmedian 30.6x
P/S now vs peer median —median 2.7x 0.6xmedian 8.8x 3.4xmedian 3.0x
EV/EBITDA now vs peer median —median 37.7x —median 17.1x 17.4xmedian 17.5x
P/FCF now vs peer median -6.8xmedian 20.7x 7.6xmedian 18.0x 35.2xmedian 23.3x
P/B now vs peer median 0.5xmedian 2.9x 0.6xmedian 2.1x 7.3xmedian 2.4x
PEG now vs peer median —median 2.04 —median 0.31 0.34median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGELSGRFSPODD
Revenue – – $3.05B
Gross profit – – $2.17B
Operating income – – $515.80M
Net income – – $375.30M
Free cash flow – – $293.70M
R&D – – $345.90M
EPS (diluted) – – $5.41
Cash & equivalents $6.26K $969.15M $534.90M
Total debt $8.91M $44.00B $3.86B
Shares (diluted) 9.27M 681.57M 69.40M
Enterprise value $1.94M $1.86B $7.89B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGELSGRFSPODD
P/E – 11.9x 27.6x
P/FCF -6.8x 7.6x 35.2x
P/Operating cash flow – – 20.3x
P/S – 0.6x 3.4x
P/B 0.5x 0.6x 7.3x
P/Tangible book -1.4x 0.9x 7.9x
EV/EBITDA – – 17.4x
EV/EBIT – – 20.9x
EV/Revenue – – 3.5x
EV/FCF – – 36.7x
EV/Operating cash flow – – 21.1x
PEG (3Y EPS CAGR) – – 0.34

Growth

14 metrics
MetricGELSGRFSPODD
Revenue growth (1Y) – – 29.4%
Revenue CAGR (3Y) – – 27.7%
Gross profit growth (1Y) – – 30.0%
Gross profit CAGR (3Y) – – 33.6%
Operating income growth (1Y) – – 26.6%
Operating income CAGR (3Y) – – 82.3%
Net income growth (1Y) – – 59.0%
Net income CAGR (3Y) – – 81.4%
EPS growth (1Y) – – 61.8%
EPS CAGR (3Y) – – 82.0%
Operating cash flow growth (1Y) – – -0.9%
Operating cash flow CAGR (3Y) – – 49.9%
Free cash flow growth (1Y) – – -27.5%
Free cash flow CAGR (3Y) – – 113.5%

Profitability

14 metrics
MetricGELSGRFSPODD
Gross margin – – 71.1%
EBITDA margin – – 20.2%
Operating margin – – 16.9%
Pretax margin – – 16.2%
Net margin – – 12.3%
FCF margin – – 9.6%
Operating cash flow margin – – 16.7%
Return on equity – – 27.6%
Return on assets – – 12.2%
Return on invested capital – – 16.9%
Return on capital employed – – 22.1%
Asset turnover – – 1.0x
Cash conversion (OCF / net income) – – 1.4x
Stock comp / revenue – – 2.6%

Financial Health

11 metrics
MetricGELSGRFSPODD
Debt / assets 0.1% 48.9% 30.0%
Debt / equity 0.0x 1.3x 0.7x
Net debt / EBITDA – – 0.7x
Debt / FCF – – 3.2x
Liabilities / assets 29.4% 61.4% 55.1%
Equity / assets 70.6% 38.6% 44.9%
Interest coverage – – 8.8x
Current ratio 0.1x 2.5x 2.5x
Quick ratio 0.1x 0.8x 1.5x
Cash ratio 0.0x 0.4x 0.7x
Altman Z-score – – 5.69

Shareholder Returns

7 metrics
MetricGELSGRFSPODD
Dividend yield – 1.4% –
Net buyback yield – – 3.0%
Shareholder yield – 1.4% 3.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGELSGRFSPODD
Forward P/E – 8.4xFY2026 24.3xFY2026
EPS, next fiscal year – $0.94FY2026 $6.13FY2026
EPS growth, next FY – +10.6%FY2026 +23.3%FY2026
EPS growth, the year after – +26.6% +31.2%
Revenue, next fiscal year – $8.88BFY2026 $3.41BFY2026
Revenue growth, next FY – +0.0%FY2026 +25.7%FY2026
Revenue growth, the year after – +10.3% +7.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGELSGRFSPODD
Held by institutions – 21.0% 100.0%
Institutions holding – 166 724
Change in shares held, QoQ – -0.5% +3.0%
Institutions buying – 73 419
Institutions selling – 65 245
Buyers to sellers – 1.12 1.71

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GELSGRFSPODD
GELS 1.00 0.11 0.00
GRFS 0.11 1.00 0.17
PODD 0.00 0.17 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GELS, GRFS and PODD?

Insulet (PODD) is the largest by market capitalisation: Gelteq (GELS) $4.08M, Grifols (GRFS) $5.52B, Insulet (PODD) $10.38B.

Which stock is cheaper, GELS, GRFS and PODD?

Grifols (GRFS) trades on the lowest price-to-earnings ratio (Grifols (GRFS) 11.9x, Insulet (PODD) 27.7x). On next year's consensus earnings, Grifols (GRFS) is cheapest (Grifols (GRFS) 8.4x, Insulet (PODD) 24.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which stock has performed better?

Over the past year Grifols (GRFS) returned the most: Gelteq (GELS) -63.7%, Grifols (GRFS) -16.3%, Insulet (PODD) -53.5%. Over five years, Grifols (GRFS) compounded fastest (Grifols (GRFS) -9.9%/yr, Insulet (PODD) -13.0%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Grifols (GRFS) has been the steadiest (Gelteq (GELS) 159.8%, Grifols (GRFS) 32.4%, Insulet (PODD) 46.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GELS, GRFS and PODD?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Grifols (GRFS) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.